Diabetic ketoacidosis in a patient with type I diabetes treated with tirzepatide

A dual glucagon-like peptide 1/gastric inhibitory peptide (GLP-1/GIP) analog, tirzepatide [1], is now available in France for the management of type 2 diabetes, or for weight control (BMI > = 30 kg/m² or > = 27 kg/m² with a comorbidity factor) (but not currently reimbursed by the French health...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta diabetologica Jg. 62; H. 10; S. 1825 - 1826
Hauptverfasser: Roche, Ernest, Chapon, Julie, Bogenmann, Laura, Luyton, Cédric, Marchand, Lucien
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Milan Springer Milan 01.10.2025
Springer Nature B.V
Schlagworte:
Case Report
Comorbidity
Conflicts of interest
Dehydration
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetic ketoacidosis
Emergency medical care
Gastrointestinal surgery
Glucagon
Glucagon-like peptide 1
Glucose
Hypoglycemia
Infusion pumps
Insulin
Internal Medicine
Ketoacidosis
Medicine
Medicine & Public Health
Metabolic Diseases
Overweight
Patients
Peptides
Sensors
Vitamin deficiency
Weight control
Dual glucagon-like peptide 1/gastric inhibitory peptide analog (GLP-1/GIP)
Tirzepatide
Type 1 diabetes
Diabetic ketoacidosis
ISSN:1432-5233, 0940-5429, 1432-5233
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A dual glucagon-like peptide 1/gastric inhibitory peptide (GLP-1/GIP) analog, tirzepatide [1], is now available in France for the management of type 2 diabetes, or for weight control (BMI > = 30 kg/m² or > = 27 kg/m² with a comorbidity factor) (but not currently reimbursed by the French health insurance system). Declarations Conflict of interest LM has received honoraria for speaking from Abbott, Lilly, Novo Nordisk and Sanofi. ER, LB and JC have no potential conflict of interest relevant to this article.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1432-5233
0940-5429
1432-5233
DOI:10.1007/s00592-025-02535-x